Skip to main content
PMC home page
Postgraduate Medical Journal logoLink to Postgraduate Medical Journal
. 2005 Sep;81(959):572–579. doi: 10.1136/pgmj.2004.030692

Diagnosis and management of gout: a rational approach

E Suresh 1
PMCID: PMC1743349  PMID: 16143687

Abstract

Gout is one of the best understood among the rheumatological disorders and one of the most satisfying to treat. Even non-specialists should be able to diagnose and treat most patients provided some important principles are appreciated. Management of a minority of patients, including those with renal impairment is difficult and often unsatisfactory, because of restricted treatment options. In this paper, the basic principles underlying the diagnosis and management of gout are discussed first, followed by practical approaches.

Full Text

The Full Text of this article is available as a PDF (126.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Agudelo C. A., Schumacher H. R. The synovitis of acute gouty arthritis. A light and electron microscopic study. Hum Pathol. 1973 Jun;4(2):265–279. doi: 10.1016/s0046-8177(73)80013-9. [DOI] [PubMed] [Google Scholar]
  2. Ahern M. J., Reid C., Gordon T. P., McCredie M., Brooks P. M., Jones M. Does colchicine work? The results of the first controlled study in acute gout. Aust N Z J Med. 1987 Jun;17(3):301–304. doi: 10.1111/j.1445-5994.1987.tb01232.x. [DOI] [PubMed] [Google Scholar]
  3. Alderman M. H., Cohen H., Madhavan S., Kivlighn S. Serum uric acid and cardiovascular events in successfully treated hypertensive patients. Hypertension. 1999 Jul;34(1):144–150. doi: 10.1161/01.hyp.34.1.144. [DOI] [PubMed] [Google Scholar]
  4. Alloway J. A., Moriarty M. J., Hoogland Y. T., Nashel D. J. Comparison of triamcinolone acetonide with indomethacin in the treatment of acute gouty arthritis. J Rheumatol. 1993 Jan;20(1):111–113. [PubMed] [Google Scholar]
  5. Arai Makoto, Yokosuka Osamu, Fujiwara Keiichi, Kojima Hiroshige, Kanda Tatsuo, Hirasawa Hiroyuki, Saisho Hiromitsu. Fulminant hepatic failure associated with benzbromarone treatment: a case report. J Gastroenterol Hepatol. 2002 May;17(5):625–626. doi: 10.1046/j.1440-1746.2002.02692.x. [DOI] [PubMed] [Google Scholar]
  6. Bellamy N., Downie W. W., Buchanan W. W. Observations on spontaneous improvement in patients with podagra: implications for therapeutic trials of non-steroidal anti-inflammatory drugs. Br J Clin Pharmacol. 1987 Jul;24(1):33–36. doi: 10.1111/j.1365-2125.1987.tb03132.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Bieber Jeffry D., Terkeltaub Robert A. Gout: on the brink of novel therapeutic options for an ancient disease. Arthritis Rheum. 2004 Aug;50(8):2400–2414. doi: 10.1002/art.20438. [DOI] [PubMed] [Google Scholar]
  8. Bomalaski John S., Holtsberg Frederick W., Ensor C. Mark, Clark Mike A. Uricase formulated with polyethylene glycol (uricase-PEG 20): biochemical rationale and preclinical studies. J Rheumatol. 2002 Sep;29(9):1942–1949. [PubMed] [Google Scholar]
  9. Bonora E., Targher G., Zenere M. B., Saggiani F., Cacciatori V., Tosi F., Travia D., Zenti M. G., Branzi P., Santi L. Relationship of uric acid concentration to cardiovascular risk factors in young men. Role of obesity and central fat distribution. The Verona Young Men Atherosclerosis Risk Factors Study. Int J Obes Relat Metab Disord. 1996 Nov;20(11):975–980. [PubMed] [Google Scholar]
  10. Bull P. W., Scott J. T. Intermittent control of hyperuricemia in the treatment of gout. J Rheumatol. 1989 Sep;16(9):1246–1248. [PubMed] [Google Scholar]
  11. Butler R. C., Goddard D. H., Higgens C. S., Hollingworth P., Pease C. T., Stodell M. A., Scott J. T. Double-blind trial of flurbiprofen and phenylbutazone in acute gouty arthritis. Br J Clin Pharmacol. 1985 Nov;20(5):511–513. doi: 10.1111/j.1365-2125.1985.tb05110.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Cameron J. S., Moro F., Simmonds H. A. Gout, uric acid and purine metabolism in paediatric nephrology. Pediatr Nephrol. 1993 Feb;7(1):105–118. doi: 10.1007/BF00861588. [DOI] [PubMed] [Google Scholar]
  13. Campion E. W., Glynn R. J., DeLabry L. O. Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study. Am J Med. 1987 Mar;82(3):421–426. doi: 10.1016/0002-9343(87)90441-4. [DOI] [PubMed] [Google Scholar]
  14. Caspi D., Lubart E., Graff E., Habot B., Yaron M., Segal R. The effect of mini-dose aspirin on renal function and uric acid handling in elderly patients. Arthritis Rheum. 2000 Jan;43(1):103–108. doi: 10.1002/1529-0131(200001)43:1<103::AID-ANR13>3.0.CO;2-C. [DOI] [PubMed] [Google Scholar]
  15. Cheng Tien-Tsai, Lai Han-Ming, Chiu Chun-Kai, Chem Ying-Chou. A single-blind, randomized, controlled trial to assess the efficacy and tolerability of rofecoxib, diclofenac sodium, and meloxicam in patients with acute gouty arthritis. Clin Ther. 2004 Mar;26(3):399–406. doi: 10.1016/s0149-2918(04)90035-5. [DOI] [PubMed] [Google Scholar]
  16. Choi Hyon K., Atkinson Karen, Karlson Elizabeth W., Willett Walter, Curhan Gary. Alcohol intake and risk of incident gout in men: a prospective study. Lancet. 2004 Apr 17;363(9417):1277–1281. doi: 10.1016/S0140-6736(04)16000-5. [DOI] [PubMed] [Google Scholar]
  17. Choi Hyon K., Atkinson Karen, Karlson Elizabeth W., Willett Walter, Curhan Gary. Purine-rich foods, dairy and protein intake, and the risk of gout in men. N Engl J Med. 2004 Mar 11;350(11):1093–1103. doi: 10.1056/NEJMoa035700. [DOI] [PubMed] [Google Scholar]
  18. Clive D. M. Renal transplant-associated hyperuricemia and gout. J Am Soc Nephrol. 2000 May;11(5):974–979. doi: 10.1681/ASN.V115974. [DOI] [PubMed] [Google Scholar]
  19. Culleton B. F., Larson M. G., Kannel W. B., Levy D. Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Ann Intern Med. 1999 Jul 6;131(1):7–13. doi: 10.7326/0003-4819-131-1-199907060-00003. [DOI] [PubMed] [Google Scholar]
  20. Dessein P. H., Shipton E. A., Stanwix A. E., Joffe B. I., Ramokgadi J. Beneficial effects of weight loss associated with moderate calorie/carbohydrate restriction, and increased proportional intake of protein and unsaturated fat on serum urate and lipoprotein levels in gout: a pilot study. Ann Rheum Dis. 2000 Jul;59(7):539–543. doi: 10.1136/ard.59.7.539. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Drenick E. J. Hyperuricemia, acute gout, renal insufficiency and urate nephrolithiasis due to starvation. Arthritis Rheum. 1965 Oct;8(5):988–997. doi: 10.1002/art.1780080509. [DOI] [PubMed] [Google Scholar]
  22. Emmerson B. T. Identification of the causes of persistent hyperuricaemia. Lancet. 1991 Jun 15;337(8755):1461–1463. doi: 10.1016/0140-6736(91)93141-u. [DOI] [PubMed] [Google Scholar]
  23. Emmerson B. T., Nagel S. L., Duffy D. L., Martin N. G. Genetic control of the renal clearance of urate: a study of twins. Ann Rheum Dis. 1992 Mar;51(3):375–377. doi: 10.1136/ard.51.3.375. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Emmerson B. T. The management of gout. N Engl J Med. 1996 Feb 15;334(7):445–451. doi: 10.1056/NEJM199602153340707. [DOI] [PubMed] [Google Scholar]
  25. Emmerson B. Hyperlipidaemia in hyperuricaemia and gout. Ann Rheum Dis. 1998 Sep;57(9):509–510. doi: 10.1136/ard.57.9.509. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Fam A. G., Dunne S. M., Iazzetta J., Paton T. W. Efficacy and safety of desensitization to allopurinol following cutaneous reactions. Arthritis Rheum. 2001 Jan;44(1):231–238. doi: 10.1002/1529-0131(200101)44:1<231::AID-ANR30>3.0.CO;2-7. [DOI] [PubMed] [Google Scholar]
  27. Fam A. G., Lewtas J., Stein J., Paton T. W. Desensitization to allopurinol in patients with gout and cutaneous reactions. Am J Med. 1992 Sep;93(3):299–302. doi: 10.1016/0002-9343(92)90236-5. [DOI] [PubMed] [Google Scholar]
  28. Fam Adel G. Gout, diet, and the insulin resistance syndrome. J Rheumatol. 2002 Jul;29(7):1350–1355. [PubMed] [Google Scholar]
  29. Faraj A. A., Omonbude O. D., Godwin P. Gram staining in the diagnosis of acute septic arthritis. Acta Orthop Belg. 2002 Oct;68(4):388–391. [PubMed] [Google Scholar]
  30. Fernández C., Noguera R., González J. A., Pascual E. Treatment of acute attacks of gout with a small dose of intraarticular triamcinolone acetonide. J Rheumatol. 1999 Oct;26(10):2285–2286. [PubMed] [Google Scholar]
  31. Fruehwald-Schultes B., Peters A., Kern W., Beyer J., Pfützner A. Serum leptin is associated with serum uric acid concentrations in humans. Metabolism. 1999 Jun;48(6):677–680. doi: 10.1016/s0026-0495(99)90163-4. [DOI] [PubMed] [Google Scholar]
  32. Gibson T., Waterworth R., Hatfield P., Robinson G., Bremner K. Hyperuricaemia, gout and kidney function in New Zealand Maori men. Br J Rheumatol. 1984 Nov;23(4):276–282. doi: 10.1093/rheumatology/23.4.276. [DOI] [PubMed] [Google Scholar]
  33. Groff G. D., Franck W. A., Raddatz D. A. Systemic steroid therapy for acute gout: a clinical trial and review of the literature. Semin Arthritis Rheum. 1990 Jun;19(6):329–336. doi: 10.1016/0049-0172(90)90070-v. [DOI] [PubMed] [Google Scholar]
  34. Hadler N. M., Franck W. A., Bress N. M., Robinson D. R. Acute polyarticular gout. Am J Med. 1974 May;56(5):715–719. doi: 10.1016/0002-9343(74)90639-1. [DOI] [PubMed] [Google Scholar]
  35. Hande K. R., Noone R. M., Stone W. J. Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med. 1984 Jan;76(1):47–56. doi: 10.1016/0002-9343(84)90743-5. [DOI] [PubMed] [Google Scholar]
  36. Harris C. M., Lloyd D. C., Lewis J. The prevalence and prophylaxis of gout in England. J Clin Epidemiol. 1995 Sep;48(9):1153–1158. doi: 10.1016/0895-4356(94)00244-k. [DOI] [PubMed] [Google Scholar]
  37. Hepburn A. L., Kaye S. A., Feher M. D. Long-term remission from gout associated with fenofibrate therapy. Clin Rheumatol. 2003 Feb;22(1):73–76. doi: 10.1007/s10067-002-0658-1. [DOI] [PubMed] [Google Scholar]
  38. Jossa F., Farinaro E., Panico S., Krogh V., Celentano E., Galasso R., Mancini M., Trevisan M. Serum uric acid and hypertension: the Olivetti heart study. J Hum Hypertens. 1994 Sep;8(9):677–681. [PubMed] [Google Scholar]
  39. Jüni Peter, Nartey Linda, Reichenbach Stephan, Sterchi Rebekka, Dieppe Paul A., Egger Matthias. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet. 2004 Dec 4;364(9450):2021–2029. doi: 10.1016/S0140-6736(04)17514-4. [DOI] [PubMed] [Google Scholar]
  40. KELLGREN J. H., LAWRENCE J. S. Osteo-arthrosis and disk degeneration in an urban population. Ann Rheum Dis. 1958 Dec;17(4):388–397. doi: 10.1136/ard.17.4.388. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Kippen I., Klinenberg J. R., Weinberger A., Wilcox W. R. Factors affecting urate solubility in vitro. Ann Rheum Dis. 1974 Jul;33(4):313–317. doi: 10.1136/ard.33.4.313. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Kot T. V., Day R. O., Brooks P. M. Preventing acute gout when starting allopurinol therapy. Colchicine or NSAIDs? Med J Aust. 1993 Aug 2;159(3):182–184. [PubMed] [Google Scholar]
  43. Kuncl R. W., Duncan G., Watson D., Alderson K., Rogawski M. A., Peper M. Colchicine myopathy and neuropathy. N Engl J Med. 1987 Jun 18;316(25):1562–1568. doi: 10.1056/NEJM198706183162502. [DOI] [PubMed] [Google Scholar]
  44. Langlois Michel, De Bacquer Dirk, Duprez Daniel, De Buyzere Marc, Delanghe Joris, Blaton Victor. Serum uric acid in hypertensive patients with and without peripheral arterial disease. Atherosclerosis. 2003 May;168(1):163–168. doi: 10.1016/s0021-9150(03)00093-5. [DOI] [PubMed] [Google Scholar]
  45. Lawrence R. C., Helmick C. G., Arnett F. C., Deyo R. A., Felson D. T., Giannini E. H., Heyse S. P., Hirsch R., Hochberg M. C., Hunder G. G. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum. 1998 May;41(5):778–799. doi: 10.1002/1529-0131(199805)41:5<778::AID-ART4>3.0.CO;2-V. [DOI] [PubMed] [Google Scholar]
  46. Lehto S., Niskanen L., Rönnemaa T., Laakso M. Serum uric acid is a strong predictor of stroke in patients with non-insulin-dependent diabetes mellitus. Stroke. 1998 Mar;29(3):635–639. doi: 10.1161/01.str.29.3.635. [DOI] [PubMed] [Google Scholar]
  47. Lin H. Y., Rocher L. L., McQuillan M. A., Schmaltz S., Palella T. D., Fox I. H. Cyclosporine-induced hyperuricemia and gout. N Engl J Med. 1989 Aug 3;321(5):287–292. doi: 10.1056/NEJM198908033210504. [DOI] [PubMed] [Google Scholar]
  48. Lin K. C., Lin H. Y., Chou P. The interaction between uric acid level and other risk factors on the development of gout among asymptomatic hyperuricemic men in a prospective study. J Rheumatol. 2000 Jun;27(6):1501–1505. [PubMed] [Google Scholar]
  49. Loeb J. N. The influence of temperature on the solubility of monosodium urate. Arthritis Rheum. 1972 Mar-Apr;15(2):189–192. doi: 10.1002/art.1780150209. [DOI] [PubMed] [Google Scholar]
  50. Lomen P. L., Turner L. F., Lamborn K. R., Winblad M. A., Sack R. L., Brinn E. L. Flurbiprofen in the treatment of acute gout. A comparison with indomethacin. Am J Med. 1986 Mar 24;80(3A):134–139. doi: 10.1016/0002-9343(86)90131-2. [DOI] [PubMed] [Google Scholar]
  51. Maccagno A., Di Giorgio E., Romanowicz A. Effectiveness of etodolac ('Lodine') compared with naproxen in patients with acute gout. Curr Med Res Opin. 1991;12(7):423–429. doi: 10.1185/03007999109111513. [DOI] [PubMed] [Google Scholar]
  52. McGill N. W. Gout and other crystal-associated arthropathies. Baillieres Best Pract Res Clin Rheumatol. 2000 Sep;14(3):445–460. doi: 10.1053/berh.2000.0087. [DOI] [PubMed] [Google Scholar]
  53. McInnes G. T., Lawson D. H., Jick H. Acute adverse reactions attributed to allopurinol in hospitalised patients. Ann Rheum Dis. 1981 Jun;40(3):245–249. doi: 10.1136/ard.40.3.245. [DOI] [PMC free article] [PubMed] [Google Scholar]
  54. Morris Ian, Varughese George, Mattingly Peter. Colchicine in acute gout. BMJ. 2003 Nov 29;327(7426):1275–1276. doi: 10.1136/bmj.327.7426.1275. [DOI] [PMC free article] [PubMed] [Google Scholar]
  55. Moyer Robert A., John Douglas St. Acute gout precipitated by total parenteral nutrition. J Rheumatol. 2003 Apr;30(4):849–850. [PubMed] [Google Scholar]
  56. Muscelli E., Natali A., Bianchi S., Bigazzi R., Galvan A. Q., Sironi A. M., Frascerra S., Ciociaro D., Ferrannini E. Effect of insulin on renal sodium and uric acid handling in essential hypertension. Am J Hypertens. 1996 Aug;9(8):746–752. doi: 10.1016/0895-7061(96)00098-2. [DOI] [PubMed] [Google Scholar]
  57. Nicholls A., Snaith M. L., Scott J. T. Effect of oestrogen therapy on plasma and urinary levels of uric acid. Br Med J. 1973 Feb 24;1(5851):449–451. doi: 10.1136/bmj.1.5851.449. [DOI] [PMC free article] [PubMed] [Google Scholar]
  58. Niskanen Leo K., Laaksonen David E., Nyyssönen Kristiina, Alfthan Georg, Lakka Hanna-Maaria, Lakka Timo A., Salonen Jukka T. Uric acid level as a risk factor for cardiovascular and all-cause mortality in middle-aged men: a prospective cohort study. Arch Intern Med. 2004 Jul 26;164(14):1546–1551. doi: 10.1001/archinte.164.14.1546. [DOI] [PubMed] [Google Scholar]
  59. Pascual E., Batlle-Gualda E., Martínez A., Rosas J., Vela P. Synovial fluid analysis for diagnosis of intercritical gout. Ann Intern Med. 1999 Nov 16;131(10):756–759. doi: 10.7326/0003-4819-131-10-199911160-00007. [DOI] [PubMed] [Google Scholar]
  60. Pascual E. Persistence of monosodium urate crystals and low-grade inflammation in the synovial fluid of patients with untreated gout. Arthritis Rheum. 1991 Feb;34(2):141–145. doi: 10.1002/art.1780340203. [DOI] [PubMed] [Google Scholar]
  61. Perez-Ruiz F., Calabozo M., Erauskin G. García, Ruibal A., Herrero-Beites A. M. Renal underexcretion of uric acid is present in patients with apparent high urinary uric acid output. Arthritis Rheum. 2002 Dec 15;47(6):610–613. doi: 10.1002/art.10792. [DOI] [PubMed] [Google Scholar]
  62. Perez-Ruiz Fernando, Calabozo Marcelo, Pijoan Jose I., Herrero-Beites Ana M., Ruibal Ana. Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. Arthritis Rheum. 2002 Aug;47(4):356–360. doi: 10.1002/art.10511. [DOI] [PubMed] [Google Scholar]
  63. Popp J. D., Bidgood W. D., Jr, Edwards N. L. Magnetic resonance imaging of tophaceous gout in the hands and wrists. Semin Arthritis Rheum. 1996 Feb;25(4):282–289. doi: 10.1016/s0049-0172(96)80038-2. [DOI] [PubMed] [Google Scholar]
  64. Rathmann W., Funkhouser E., Dyer A. R., Roseman J. M. Relations of hyperuricemia with the various components of the insulin resistance syndrome in young black and white adults: the CARDIA study. Coronary Artery Risk Development in Young Adults. Ann Epidemiol. 1998 May;8(4):250–261. doi: 10.1016/s1047-2797(97)00204-4. [DOI] [PubMed] [Google Scholar]
  65. Rich M. W. Uric acid: is it a risk factor for cardiovascular disease? Am J Cardiol. 2000 Apr 15;85(8):1018–1021. doi: 10.1016/s0002-9149(99)00922-4. [DOI] [PubMed] [Google Scholar]
  66. Riedel Aylin A., Nelson Michael, Joseph-Ridge Nancy, Wallace Katrine, MacDonald Patricia, Becker Michael. Compliance with allopurinol therapy among managed care enrollees with gout: a retrospective analysis of administrative claims. J Rheumatol. 2004 Aug;31(8):1575–1581. [PubMed] [Google Scholar]
  67. Roseff R., Wohlgethan J. R., Sipe J. D., Canoso J. J. The acute phase response in gout. J Rheumatol. 1987 Oct;14(5):974–977. [PubMed] [Google Scholar]
  68. Sarkozi J. Management of gout. N Engl J Med. 1996 Jun 6;334(23):1543–1544. doi: 10.1056/NEJM199606063342313. [DOI] [PubMed] [Google Scholar]
  69. Schiltz Corinne, Lioté F., Prudhommeaux F., Meunier A., Champy R., Callebert J., Bardin T. Monosodium urate monohydrate crystal-induced inflammation in vivo: quantitative histomorphometric analysis of cellular events. Arthritis Rheum. 2002 Jun;46(6):1643–1650. doi: 10.1002/art.10326. [DOI] [PubMed] [Google Scholar]
  70. Schumacher H. Ralph, Jr, Boice Judith A., Daikh David I., Mukhopadhyay Saurabh, Malmstrom Kerstin, Ng Jennifer, Tate Guillermo A., Molina Javier. Randomised double blind trial of etoricoxib and indometacin in treatment of acute gouty arthritis. BMJ. 2002 Jun 22;324(7352):1488–1492. doi: 10.1136/bmj.324.7352.1488. [DOI] [PMC free article] [PubMed] [Google Scholar]
  71. Shmerling R. H., Stern S. H., Gravallese E. M., Kantrowitz F. G. Tophaceous deposition in the finger pads without gouty arthritis. Arch Intern Med. 1988 Aug;148(8):1830–1832. [PubMed] [Google Scholar]
  72. Shoji Akira, Yamanaka Hisashi, Kamatani Naoyuki. A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Arthritis Rheum. 2004 Jun 15;51(3):321–325. doi: 10.1002/art.20405. [DOI] [PubMed] [Google Scholar]
  73. Siegel L. B., Alloway J. A., Nashel D. J. Comparison of adrenocorticotropic hormone and triamcinolone acetonide in the treatment of acute gouty arthritis. J Rheumatol. 1994 Jul;21(7):1325–1327. [PubMed] [Google Scholar]
  74. Simkin P. A. The pathogenesis of podagra. Ann Intern Med. 1977 Feb;86(2):230–233. doi: 10.7326/0003-4819-86-2-230. [DOI] [PubMed] [Google Scholar]
  75. Simmonds H. A., McBride M. B., Hatfield P. J., Graham R., McCaskey J., Jackson M. Polynesian women are also at risk for hyperuricaemia and gout because of a genetic defect in renal urate handling. Br J Rheumatol. 1994 Oct;33(10):932–937. doi: 10.1093/rheumatology/33.10.932. [DOI] [PubMed] [Google Scholar]
  76. Snaith M. A (very) short history of diets for gout. Rheumatology (Oxford) 2004 Aug;43(8):1054–1054. doi: 10.1093/rheumatology/keh019. [DOI] [PubMed] [Google Scholar]
  77. Spilberg I., Mandell B., Mehta J., Simchowitz L., Rosenberg D. Mechanism of action of colchicine in acute urate crystal-induced arthritis. J Clin Invest. 1979 Sep;64(3):775–780. doi: 10.1172/JCI109523. [DOI] [PMC free article] [PubMed] [Google Scholar]
  78. Takahashi S., Moriwaki Y., Yamamoto T., Tsutsumi Z., Ka T., Fukuchi M. Effects of combination treatment using anti-hyperuricaemic agents with fenofibrate and/or losartan on uric acid metabolism. Ann Rheum Dis. 2003 Jun;62(6):572–575. doi: 10.1136/ard.62.6.572. [DOI] [PMC free article] [PubMed] [Google Scholar]
  79. Urano Wako, Yamanaka Hisashi, Tsutani Hiroshi, Nakajima Hiroshi, Matsuda Yuko, Taniguchi Atsuo, Hara Masako, Kamatani Naoyuki. The inflammatory process in the mechanism of decreased serum uric acid concentrations during acute gouty arthritis. J Rheumatol. 2002 Sep;29(9):1950–1953. [PubMed] [Google Scholar]
  80. Venkat Raman G., Sharman V. L., Lee H. A. Azathioprine and allopurinol: a potentially dangerous combination. J Intern Med. 1990 Jul;228(1):69–71. doi: 10.1111/j.1365-2796.1990.tb00195.x. [DOI] [PubMed] [Google Scholar]
  81. Vázquez-Mellado Janitzia, Alvarez Hernández Everardo, Burgos-Vargas Rubén. Primary prevention in rheumatology: the importance of hyperuricemia. Best Pract Res Clin Rheumatol. 2004 Apr;18(2):111–124. doi: 10.1016/j.berh.2004.01.001. [DOI] [PubMed] [Google Scholar]
  82. Wannamethee S. G., Shaper A. G., Whincup P. H. Serum urate and the risk of major coronary heart disease events. Heart. 1997 Aug;78(2):147–153. doi: 10.1136/hrt.78.2.147. [DOI] [PMC free article] [PubMed] [Google Scholar]
  83. Weinberger A., Schumacher H. R., Agudelo C. A. Urate crystals in asymptomatic metatarsophalangeal joints. Ann Intern Med. 1979 Jul;91(1):56–57. doi: 10.7326/0003-4819-91-1-56. [DOI] [PubMed] [Google Scholar]
  84. Wortmann R. L. Effective management of gout: an analogy. Am J Med. 1998 Dec;105(6):513–514. doi: 10.1016/s0002-9343(98)00323-4. [DOI] [PubMed] [Google Scholar]
  85. YU T. F., GUTMAN A. B. Efficacy of colchicine prophylaxis in gout. Prevention of recurrent gouty arthritis over a mean period of five years in 208 gouty subjects. Ann Intern Med. 1961 Aug;55:179–192. doi: 10.7326/0003-4819-55-2-179. [DOI] [PubMed] [Google Scholar]
  86. Young J. L., Jr, Boswell R. B., Nies A. S. Severe allopurinol hypersensitivity. Association with thiazides and prior renal compromise. Arch Intern Med. 1974 Sep;134(3):553–558. doi: 10.1001/archinte.134.3.553. [DOI] [PubMed] [Google Scholar]
  87. Yu K. H., Luo S. F., Liou L. B., Wu Y-J J., Tsai W. P., Chen J. Y., Ho H. H. Concomitant septic and gouty arthritis--an analysis of 30 cases. Rheumatology (Oxford) 2003 Apr 16;42(9):1062–1066. doi: 10.1093/rheumatology/keg297. [DOI] [PubMed] [Google Scholar]
  88. Yü T., Gutman A. B. Uric acid nephrolithiasis in gout. Predisposing factors. Ann Intern Med. 1967 Dec;67(6):1133–1148. doi: 10.7326/0003-4819-67-6-1133. [DOI] [PubMed] [Google Scholar]
  89. Zürcher R. M., Bock H. A., Thiel G. Excellent uricosuric efficacy of benzbromarone in cyclosporin-A-treated renal transplant patients: a prospective study. Nephrol Dial Transplant. 1994;9(5):548–551. doi: 10.1093/ndt/9.5.548. [DOI] [PubMed] [Google Scholar]
  90. van Lieshout-Zuidema M. F., Breedveld F. C. Withdrawal of longterm antihyperuricemic therapy in tophaceous gout. J Rheumatol. 1993 Aug;20(8):1383–1385. [PubMed] [Google Scholar]

Articles from Postgraduate Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES